Kiadis Pharma is developing potentially life‑saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant unmet medical need.
Their ATIR (Allodepleted T-cell ImmunotheRapeutics) is designed to support the patient’s newly transplanted immune system before it becomes fully functional. In ATIR, T-cells causing Graft-versus-Host-Disease (GVHD) have been depleted, while T-cells protective against tumor cells and infections have been retained.
The Company’s lead product, ATIR101, addresses key risks and limitations of HSCT in blood cancers, specifically GVHD and cancer relapse. ATIR101 is a cellular product for infusion. It consist of donor lymphocytes (immune cells), specifically manufactured for each individual patient from a healthy, haploidentical stem cell donor.
Using the Company’s proprietary selective cytotoxic compound, TH9402, those T-cells which attack the patient, causing Graft-versus-Host Disease (GVHD), are depleted. The full immune repertoire of other donor immune cells, including immunological memory, is retained in the final product.